Shifting the Paradigm of Cancer Treatment: How Can Optical Imaging Help?
Presenter: Dr Yinfei Yin
Friday October 30th, 9am ET/1pm BST;
1pm ET/5pm BST
Cancer treatment has undergone a recent paradigm shift, first towards targeted and then immuno-oncology agents. Current treatment strategies combine a range of different therapies, and drug developers are continually looking for more relevant preclinical models to address the key questions they are facing.
Optical imaging provides unique, well-characterized and robust models to improve the predictive power of preclinical studies, allowing more efficient and cost-effective translation into the clinic. In this webinar, Dr Yinfei Yin will discuss the value of optical imaging models in preclinical oncology research, with an emphasis on immunotherapy development. He’ll also highlight the key new imaging models developed for evaluating novel anticancer agents.
Attend this Webinar to:
- Explore the advantages of orthotopic syngeneic models, including organ-specific tumor microenvironments, development of relevant tumor vasculature, and stromal interactions
- Understand the difference between orthotopic and subcutaneous syngeneic models in their response to checkpoint inhibitors
- Discover how optical imaging allows real-time monitoring of tumor burden and tracking of disease progression, including for deep lying organs such as brain, prostate, and liver
- Explore the insights bioluminescent imaging provides on disease mechanisms, as well as treatment of tumorigenesis and metastasis
- Learn about unique imaging models, including engineered models and tumor homografts, engineered models to expand syngeneic tumor sources
Who Should Attend:
- Oncology program leaders who want to maximize the translatability of their immuno-oncology preclinical studies
- Scientists interested in staying up to date on in vivo imaging and how imaging is used to assess immunotherapy efficacy and compound mechanism of action
- Researchers looking to understand how in vivo models, partnered with bioluminescent imaging, can be used to interrogate I/O drug mechanism of action and TME
About The Presenter:
Dr Yinfei Yin leads the Scientific Operations team at CrownBio’s UK site and is also the head of CrownBio’s Global Imaging Platform. In these roles, Yinfei has developed a wide range of in vivo models such as metastasis, orthotopic, and traditional subcutaneous models, to support key client decisions and successful drug discovery programs.
Prior to joining CrownBio, Yinfei worked at the University of Nottingham’s Ex Vivo Cancer Pharmacology Centre of Excellence in the development of a bioluminescence and fluorescence-aided pharmaceutical candidate validation platform. Yinfei received his PhD from the University of Nottingham working on the role of Helicobacter pylori-stimulated EGF receptor in cancer invasion and metastasis.